Dr. Anne Winkler, M.D., Ph.D. – Rheumatology

//Dr. Anne Winkler, M.D., Ph.D. – Rheumatology
Dr. Anne Winkler, M.D., Ph.D. – Rheumatology2018-04-10T17:35:07+00:00
Dr. David McLaren, MD

PSN Rheumatologist: Dr. Anne Winkler, M.D., Ph.D.

Dr. Anne Winkler, M.D., Ph.D, received her medical degree from the University of Missouri-Columbia, where she also completed her residency in Internal Medicine and her Fellowship in Rheumatology. She completed her PhD in Microbiology at the University of Missouri-Columbia as well. She has practiced Rheumatology in the Springfield area since 1989.

She has published over 15 papers in the area of Rheumatology, and continues to serve as principle investigator in clinical research trials. Dr. Winkler has won the 417 Magazine Best Doctor in Rheumatology in 2009, 2008, 2006, 2005, 2003 and 2002. She has also served as Governor of the American College of Physicians (ACP). Dr. Winkler was awarded mastership in the ACP in 2008.

PhD: PhD, Microbiology
University of Missouri
Columbia, Missouri
1985 – 1989

MD: Doctor of Medicine
University of Missouri
Columbia, Missouri
1977 – 1981

BA: Bachelor of Arts
University of Pennsylvania
1971 – 1974

Residency:  Resident, Internal Medicine
University of Missouri
Columbia, Missouri
1981 – 1984

Fellowship: Fellow, Division of Immunology/Rheumatology
University of Missouri
Columbia, MO

2007 – Voted Springfield’s Best Rheumatologist

2005 – Voted Springfield’s Best Rheumatologist

2003 – Voted Springfield’s Best Rheumatologist

2003 – Woman of the Year, Springfield Business Journal

2002 – Voted Springfield’s Best Rheumatologist

2002 – Lifetime Member of Who’s Who

1996 – Who’s Who of American Women

1995 – International Who’s Who of Professionals

1994 – Fellow, American College of Physicians

1991 – Who’s Who in Medicine

1987 – 1989 – Arthritis Foundation Postdoctoral Fellow Grant

1986 – Diplomate, Subspecialty – Rheumatology, American Board of Internal Medicine

1984 – Diplomate, American Board of Internal Medicine

1981 – Licensure, State of Missouri

1974 – Phi Beta Kappa

1974 – Magna cum laude, University of Pennsylvania

1972, 1973, 1974 – Academic Distinction, University of Pennsylvania

1971 – National Merit Finalist

  • American Medical Women’s Association, 1980 – present
  • American College of Physicians, 1989 – present
  • Association for the Advancement of Science, 1984 – present
  • American College of Rheumatology, 1989 – present
  • Southwest Regional Arthritis Center at St. John’s Regional Health Center, 1989 – present
  • Missouri Juvenile Arthritis Task Force, 1991 – 1992
  • Missouri Arthritis Advisory Board, 1990 – present
  • St. John’s Medical Research Institute Board, 2007 – present
  • The Summit Preparatory School Board 2004 – present
  • 2007 – present: Member, St. John’s Medical Research Institute Board
  • 2005 – 2007: Leader, Midwest Rheumatology Association, Ozark Branch
  • 2004 – present: Chair, The Summit Preparatory School Board of Trustees
  • 2003 – 2007: Governor, ACP
  • 2002 – 2005: Leader, Women Physicians Group
  • 2002 – 2003: Governor – Elect, ACP
  • 1999 – 2002: Council Member, Missouri ACP
  • 1998 –2000: Chair, Physician Manpower Committee
  • 1998 – present: Medical Editor, Southwest Missouri Regional Arthritis Center Newsletter
  • 1998 – present: Medical Director, Fibromyalgia Support Services, St. John’s Hammons Heart Institute
  • 1996 – present: Activities Committee, Missouri ACP
  • 1994 – present: Medical Advisor, Fibromyalgia Support Group
  • 1993 – 1994: Chair, Department of Medicine Subspecialties
  • 1990 present: Medical Director, Ozark Lupus Group
  • 1990present: Women Physicians’ Committee, Missouri ACP
  • 1989 – present: Assistant Medical Director, Southwest Missouri Regional Arthritis Center
  1. Winkler, A. and D. Wilson: Thyroid acropachy: case report and review of the literature.
    1985. Missouri Med 82:756-780.
  2. Winkler A., Finan, M., Pressly T. and R. Roberts: CMV retinitis in rheumatologic disease.
    1987. Arthritis and Rheum 30:106-108.
  3. Pressly, T., Scott W., Ide, C., Winkler, A. and G. Reams:  Ocular complications of Tangier’s
    disease. 1987. Amer J Med 83:991-994.
  4. Smith, H.L., Pressly, T., Watts, C., Winkler, A. and J. Bryan: Neurosarcoid presenting as ataxia
    with CT and MRI findings: case report and discussion. 1987. Clin Neuroscience 1:10-11.
  5. Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody recognizing a unique
    subset of snRNP complexes. 1988 J. Immunol 140:69-77.
  6. Winkler, A., Jackson, R., Kay, D., Mitchell, E., Carmiagnini, S. and G. Sharp: Successful
    treatment of SLE-associated aplastic anemia. 1988. Arthritis and Rheum 41:643-644.
  7.  Winkler, A., Pressly, T. and D. Wilson: Androgen deficient osteoporosis. 1988. Missouri
    Med 85:84-86.
  8. Winkler, A., Pressly, T., Alpert, M., Jackson, R., Mukerji, V. and G. Sharp: Value and
    limitation of calcium channel blockade in patients with pulmonary arterial hypertension
    associated with CREST. 1988. Angiology 39:385-389.
  9. Pressly, T., Treadwell, E., Ansbacher, L., Winkler, A. and S. Walker: Eosinophilic fascitis,
    porphyria cutanea tarda and granulocytopenia in a patient with inflammatory arthritis. 1989.
    J. Rheum.
  10. Winkler, A., Kreivi, J.P., Akusjarvi, G. and K.S. Wise: Monoclonal autoantibody recognizes
    higher order snRNP complex involved in splicing. Submitted.
  11. Takeda, Y., Nyman, N., Winkler, A., Wise, K.S., Hoch, S.O., Pettersson, I., Anderson, S.K.,
    Wang, R.J., Wang, G.S. and G.C. Sharp: Epitope mapping of the UI snRNP – associated
    70K polypeptide. 1990. Clin Immunol Immunopath.
  12. Anderson, Frances and A Winkler: Benefits of Long-Term Fibromyalgia Treatment with
    Multi-disciplinary Program. J Musculoskeletal Diseases, Dec 2006.
  13. Kurland, Winkler and Coyle: Prevalence of Irritable Bowel Syndrome and Deression in
    Fibromyalgia. Digestive Disease and Science. 51 (3) 454-460.
  14. Anderson, Frances and A Winkler. Group Therapy in Fibromyalgia. In Press: J
    Musculoskeletal Diseases.
  1. Winkler, A., McKown, R. and K.S. Wise: Novel monoclonal autoantibody specificity associated
    with ribonucleoprotein complexes. 1986. Fed Proceedings 45:492 (Abstract 1968).
  2. Pressly, T., Winkler, A. and D. Wilson: Male osteoporosis: 2 unusual cases. 1987. Southern
    Medical Association, 81st
    Annual Scientific Assembly.
  3.  Pressly, T., Winkler, A., Alpert, M., Mukerji, V. and G. Sharp: Value and limitations of calcium
    channel blockade in patients with pulmonary arterial hypertension associated with the Crest
    syndrome. 1987. American College of Angiology , 34th Annual Meeting.
  4. Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody which recognizes a unique
    subset of snRNP. Mol Biol Reports 12:164.
  5. Pettersson, I., Nyman, U., Winkler, A., Wise, K.S. and N. Ringertz: Colocalization studies of
    different sets of snRNP using monoclonal autoantibodies. 1987. EMBO Eukaryotic RNP
    Meeting.
  6. Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody recognizing higher order
    snRNP complexes. 1987. Arthritis Foundation Fellows Conference.
  7. Takeda, Y., Nyman, N., Winkler, A., Wise, K.S., Hoch, S.O., Pettersson, I., Anderson, S.K.,
    Wang, R.J., Wang, G.S. and G.C. Sharp: Epitope mapping of the UI snRNP – associated 70K
    polypeptide. 1990. Arthritis Rheum 32:S26.
  1. “A Randomized, Double-Blind, Parallel Group, International Study To Evaluate The
    Safety And Efficacy Of Ocrelizumab Compared To Placebo In Patients With Active
    Rheumatoid Arthritis Who Have An Inadequate Response To At Least One AntiTNF-
    Therapy.”  Roche & Genentech, Principal Investigator.
  2. “A Phase 2, Randomized, Double-Blind, Placebo controlled, Parallel-Group Study of CP195543
    and Celecoxib Dual Therapy in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis in Subjects who are Inadequately Controlled on Methotrexate”, Pfizer,
    Principal Investigator
  3. “A Randomized, Double Blind, Parallel-group Study of Cardiovascular Safety in
    Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular
    Disease comparing Celecoxib with Naproxen and Ibupofen”, Pfizer, Principal Investigator
  4. “Long-term extension study of safety during treatment with tocilizumab (MRA) in patients
    completing treatment in MRA core studies”, Hoffman-La Roche, Ltd, Principal Investigator
  5.  “A randomized, double-blind, placebo-controlled, parallel group study of the safety and
    reduction of signs and symptoms during treatment with MRA versus placebo, in combination
    with traditional DMARD therapy in patients with moderate to severe active rheumatoid
    arthritis and an inadequate response to current DMARD therapy”, Hoffmann-La Roche Ltd,
    Principal Investigator
  6. “A 39-Week, Open-Label, Extension, A 13-Week, Multicenter, Randomized, Double-Blind,
    Double-Dummy, Placebo-Controlled, Parallel Trial of 2 Different Dose Regimens of
    Lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od)
    in Patients with Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator”,
    Novartis Pharmaceuticals, Principal Investigator
  7. “A Multi-Center Open-Label Study to Assess the Durability and Safety of the Prevention of
    Bone Loss by Treatment with GL701 (Prestara™) in Women with Systemic Lupus
    Erythematosus Receiving Treatment with Glucocorticoids”, Genelabs Technologies,
    Principal Investigator
  8. “A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily
    Celebrex® (celecoxib) vs. Placebo in the Treatment of Subjects with Osteoarthritis of the
    Knee Non-Responsive to Naproxen and Ibuprofen”, Pfizer, Principal Investigator
  9. “A Randomized, Double-Blind, Multi-Center, Placebo Controlled Study to Assess Prevention
    of Bone Loss by Treatment with GL701 (Prestara™) in Women with Systemic Lupus
    Erythematosus Receiving Treatment with Glucocorticoids”, Genelabs Technologies, Inc.,
    Principal Investigator
  10. “A 13-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,
    Parallel Trial of 2 Different Dose Regiments of Lumiracoxib (100 mg od and 200 mg od
    initial dose for two weeks followed by 100 mg od) in Patients with Primary Knee
    Osteoarthritis, using Celecoxib (200 mg od) as a Comparator”,   Novartis Pharmaceuticals
    Corporation, Principal Investigator
  11. “A Phase III, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing
    the Safety and Efficacy of Oral Febuxostat in Subjects with Gout”, TAP Pharmaceuticals,
    Principal Investigator
  12. ” Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group
    study assessing the efficacy of intravenous zoledornic acid in preventing subsequent
    osteoporotic fractures after a hip fracture”, Novartis Pharmaceuticals Corporation,
    Subinvestigator
  13. “An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of
    Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women with
    Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001”, NPS Allelix,
    Subinvestigator
  14. “Raloxifene Alendronate Comparison In Postmenopausal Women With Osteoporosis”, Eli
    Lilly, Subinvestigator
  15. “A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of
    Combination Treatment with Anakinra (IL-1ra) and PEGylated Recombinant Methionyl
    Human Soluble Tumor Necrosis Factor Receptor Type I (PEGsTNF-RI) in Subjects with
    Rheumatoid Arthritis Receiving Methotrexate”, Amgen, Inc., Principal Investigator
  16. “A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to
    Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density
    in Postmenopausal Women with Osteoporosis. (EFFECT Study-Efficacy of Fosamax vs.
    Evista Comparison Trial)”, Merck & Co., Inc., Subinvestigator
  17. “An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial with a 12-Month Interim
    Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture
    Incidence in Women with Postmenopausal Osteoporosis”, NPS Allelix, Subinvestigator
  18. “A Twelve-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of
    Oral Alendronate Sodium (70 mg Once Weekly) in Patients with Osteoporosis”, Merck &
    Co., Subinvestigator
  19. “A Randomized, Placebo-Controlled, Parallel Group, Double Blind Study to Evaluate the
    Safety and Efficacy of Rofecoxib and Celecoxib in Patients with Osteoarthritis of the Knee or
    Hip”, Merck & Co., Inc., Principal Investigator
  20. “A Randomized, Double Blind, Multi-Center Study to Evaluate the Tolerability and
    Effectiveness of Rofecoxib (VIOXX®) 25mg q.d. Vs. Naproxen 500 mg b.i.d. in Patients with
    Osteoarthritis” Merck & Co., Inc., Principal Investigator

Rheumatology Articles

Rheumatology articles covering symptoms, diagnosis, staging, treatment, prognosis, and follow-up.